Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 413

1.

A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77.

Chen X, Nagai Y, Zhu Z, Ruan H, Peehl DM, Greene MI, Zhang H.

Oncotarget. 2017 Dec 16;9(3):3631-3640. doi: 10.18632/oncotarget.23341. eCollection 2018 Jan 9.

2.

Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactions.

Bin Dhuban K, d'Hennezel E, Nagai Y, Xiao Y, Shao S, Istomine R, Alvarez F, Ben-Shoshan M, Ochs H, Mazer B, Li B, Sekine C, Berezov A, Hancock W, Torgerson TR, Greene MI, Piccirillo CA.

Sci Immunol. 2017 Jun 16;2(12). pii: eaai9297. doi: 10.1126/sciimmunol.aai9297.

PMID:
28783662
3.

Peter C. Nowell (1928-2016).

Greene MI, Moore JS.

Science. 2017 Mar 3;355(6328):913. doi: 10.1126/science.aam9738. No abstract available.

PMID:
28254903
4.

Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).

Cai Z, Zhu Z, Greene MI, Cines DB.

Autoimmun Rev. 2016 Jul;15(7):752-5. doi: 10.1016/j.autrev.2016.03.011. Epub 2016 Mar 9. Review.

5.

Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis.

Morvaridi S, Dhall D, Greene MI, Pandol SJ, Wang Q.

Sci Rep. 2015 Nov 16;5:16759. doi: 10.1038/srep16759.

6.

Atomic description of the immune complex involved in heparin-induced thrombocytopenia.

Cai Z, Yarovoi SV, Zhu Z, Rauova L, Hayes V, Lebedeva T, Liu Q, Poncz M, Arepally G, Cines DB, Greene MI.

Nat Commun. 2015 Sep 22;6:8277. doi: 10.1038/ncomms9277.

7.

Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors.

Nagai Y, Tsuchiya H, Runkle EA, Young PD, Ji MQ, Norton L, Drebin JA, Zhang H, Greene MI.

Cell Rep. 2015 Sep 29;12(12):2049-59. doi: 10.1016/j.celrep.2015.08.044. Epub 2015 Sep 10. Erratum in: Cell Rep. 2015 Oct 13;13(2):450.

8.

FOXP3⁺ regulatory T cell development and function require histone/protein deacetylase 3.

Wang L, Liu Y, Han R, Beier UH, Bhatti TR, Akimova T, Greene MI, Hiebert SW, Hancock WW.

J Clin Invest. 2015 Aug 3;125(8):3304. doi: 10.1172/JCI83084. Epub 2015 Aug 3. No abstract available.

9.

Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation.

Deng G, Nagai Y, Xiao Y, Li Z, Dai S, Ohtani T, Banham A, Li B, Wu SL, Hancock W, Samanta A, Zhang H, Greene MI.

J Biol Chem. 2015 Aug 14;290(33):20211-20. doi: 10.1074/jbc.M115.638221. Epub 2015 May 18.

10.

FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3.

Wang L, Liu Y, Han R, Beier UH, Bhatti TR, Akimova T, Greene MI, Hiebert SW, Hancock WW.

J Clin Invest. 2015 Mar 2;125(3):1111-23. doi: 10.1172/JCI77088. Epub 2015 Feb 2. Erratum in: J Clin Invest. 2015 Aug 3;125(8):3304.

11.

Multi-crystal native SAD analysis at 6 keV.

Liu Q, Guo Y, Chang Y, Cai Z, Assur Z, Mancia F, Greene MI, Hendrickson WA.

Acta Crystallogr D Biol Crystallogr. 2014 Oct;70(Pt 10):2544-57. doi: 10.1107/S1399004714013376. Epub 2014 Sep 30.

12.

Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.

Brun SN, Markant SL, Esparza LA, Garcia G, Terry D, Huang JM, Pavlyukov MS, Li XN, Grant GA, Crawford JR, Levy ML, Conway EM, Smith LH, Nakano I, Berezov A, Greene MI, Wang Q, Wechsler-Reya RJ.

Oncogene. 2015 Jul;34(29):3770-9. doi: 10.1038/onc.2014.304. Epub 2014 Sep 22.

13.

Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60.

Xiao Y, Nagai Y, Deng G, Ohtani T, Zhu Z, Zhou Z, Zhang H, Ji MQ, Lough JW, Samanta A, Hancock WW, Greene MI.

Cell Rep. 2014 Jun 12;7(5):1471-1480. doi: 10.1016/j.celrep.2014.04.021. Epub 2014 May 15.

14.

Determination of carbohydrate structure recognized by prostate-specific F77 monoclonal antibody through expression analysis of glycosyltransferase genes.

Nonaka M, Fukuda MN, Gao C, Li Z, Zhang H, Greene MI, Peehl DM, Feizi T, Fukuda M.

J Biol Chem. 2014 Jun 6;289(23):16478-86. doi: 10.1074/jbc.M114.559047. Epub 2014 Apr 21.

15.

Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array.

Gao C, Liu Y, Zhang H, Zhang Y, Fukuda MN, Palma AS, Kozak RP, Childs RA, Nonaka M, Li Z, Siegel DL, Hanfland P, Peehl DM, Chai W, Greene MI, Feizi T.

J Biol Chem. 2014 Jun 6;289(23):16462-77. doi: 10.1074/jbc.M114.558932. Epub 2014 Apr 21.

16.

In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma.

Realdon S, Dassie E, Fassan M, Dall'Olmo L, Hatem G, Buda A, Arcidiacono D, Diamantis G, Zhang H, Greene MI, Sturniolo GC, Rugge M, Alberti A, Battaglia G.

Dis Esophagus. 2015 May-Jun;28(4):394-403. doi: 10.1111/dote.12210. Epub 2014 Apr 7.

PMID:
24708360
17.

The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3.

Chen Z, Barbi J, Bu S, Yang HY, Li Z, Gao Y, Jinasena D, Fu J, Lin F, Chen C, Zhang J, Yu N, Li X, Shan Z, Nie J, Gao Z, Tian H, Li Y, Yao Z, Zheng Y, Park BV, Pan Z, Zhang J, Dang E, Li Z, Wang H, Luo W, Li L, Semenza GL, Zheng SG, Loser K, Tsun A, Greene MI, Pardoll DM, Pan F, Li B.

Immunity. 2013 Aug 22;39(2):272-85. doi: 10.1016/j.immuni.2013.08.006.

18.

Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers.

Du T, Nagai Y, Xiao Y, Greene MI, Zhang H.

Exp Mol Pathol. 2013 Aug;95(1):38-45. doi: 10.1016/j.yexmp.2013.04.003. Epub 2013 May 2.

19.

Structural and biochemical studies of RIG-I antiviral signaling.

Feng M, Ding Z, Xu L, Kong L, Wang W, Jiao S, Shi Z, Greene MI, Cong Y, Zhou Z.

Protein Cell. 2013 Feb;4(2):142-54. doi: 10.1007/s13238-012-2088-4. Epub 2012 Dec 20.

20.

Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.

Kanzaki H, Ohtaki A, Merchant FK, Greene MI, Murali R.

Exp Mol Pathol. 2013 Apr;94(2):372-9. doi: 10.1016/j.yexmp.2012.11.003. Epub 2012 Dec 5.

PMID:
23219833
21.

Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cells.

Deng G, Xiao Y, Zhou Z, Nagai Y, Zhang H, Li B, Greene MI.

Exp Mol Pathol. 2012 Dec;93(3):334-8. doi: 10.1016/j.yexmp.2012.09.013. Epub 2012 Oct 2. Review.

22.

Reversion of the ErbB malignant phenotype and the DNA damage response.

Runkle EA, Zhang H, Cai Z, Zhu Z, Karger BL, Wu SL, O'Rourke DM, Zhou Z, Wang Q, Greene MI.

Exp Mol Pathol. 2012 Dec;93(3):324-33. doi: 10.1016/j.yexmp.2012.09.007. Epub 2012 Sep 27. Review.

23.

MDM2 regulates a novel form of incomplete neoplastic transformation of Theileria parva infected lymphocytes.

Hayashida K, Kajino K, Hattori M, Wallace M, Morrison I, Greene MI, Sugimoto C.

Exp Mol Pathol. 2013 Feb;94(1):228-38. doi: 10.1016/j.yexmp.2012.08.008. Epub 2012 Sep 7.

PMID:
22981919
24.

Germinal center kinases in immune regulation.

Yin H, Shi Z, Jiao S, Chen C, Wang W, Greene MI, Zhou Z.

Cell Mol Immunol. 2012 Nov;9(6):439-45. doi: 10.1038/cmi.2012.30. Epub 2012 Sep 10. Review.

25.

Structural insights into SUN-KASH complexes across the nuclear envelope.

Wang W, Shi Z, Jiao S, Chen C, Wang H, Liu G, Wang Q, Zhao Y, Greene MI, Zhou Z.

Cell Res. 2012 Oct;22(10):1440-52. doi: 10.1038/cr.2012.126. Epub 2012 Sep 4.

26.

Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function.

Song X, Li B, Xiao Y, Chen C, Wang Q, Liu Y, Berezov A, Xu C, Gao Y, Li Z, Wu SL, Cai Z, Zhang H, Karger BL, Hancock WW, Wells AD, Zhou Z, Greene MI.

Cell Rep. 2012 Jun 28;1(6):665-75. doi: 10.1016/j.celrep.2012.04.012. Epub 2012 Jun 15.

27.

YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.

Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI, Wang Q.

Oncogene. 2013 Apr 25;32(17):2220-9. doi: 10.1038/onc.2012.231. Epub 2012 Jun 11.

28.

The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.

McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE, Gabra H.

Cancer Discov. 2012 Feb;2(2):156-71. doi: 10.1158/2159-8290.CD-11-0256.

29.

A structural modulator of tumor necrosis factor type 1 receptor promotes bone formation under lipopolysaccharide-induced inflammation in a murine tooth extraction model.

Nakachi H, Aoki K, Tomomatsu N, Alles N, Nagano K, Yamashiro M, Zhang H, Murali R, Greene MI, Ohya K, Amagasa T.

Eur J Pharmacol. 2012 Mar 15;679(1-3):132-8. doi: 10.1016/j.ejphar.2011.12.046. Epub 2012 Jan 20.

PMID:
22290392
30.

Structure based antibody-like peptidomimetics.

Murali R, Greene MI.

Pharmaceuticals (Basel). 2012 Feb 16;5(2):209-35. doi: 10.3390/ph5020209.

31.

Structure of Sad1-UNC84 homology (SUN) domain defines features of molecular bridge in nuclear envelope.

Zhou Z, Du X, Cai Z, Song X, Zhang H, Mizuno T, Suzuki E, Yee MR, Berezov A, Murali R, Wu SL, Karger BL, Greene MI, Wang Q.

J Biol Chem. 2012 Feb 17;287(8):5317-26. doi: 10.1074/jbc.M111.304543. Epub 2011 Dec 14.

32.

Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity.

Zhang H, Xiao Y, Zhu Z, Li B, Greene MI.

Immunol Cell Biol. 2012 Jan;90(1):95-100. doi: 10.1038/icb.2011.101. Epub 2011 Nov 29. Review.

33.

Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.

Mori T, Nishizawa S, Hirohashi Y, Torigoe T, Tamura Y, Takahashi A, Kochin V, Fujii R, Kondo T, Greene MI, Hara I, Sato N.

Exp Mol Pathol. 2012 Feb;92(1):27-32. doi: 10.1016/j.yexmp.2011.09.016. Epub 2011 Oct 2.

PMID:
22001602
34.

Expression and function of ErbB receptors and ligands in the pituitary.

Cooper O, Vlotides G, Fukuoka H, Greene MI, Melmed S.

Endocr Relat Cancer. 2011 Oct 27;18(6):R197-211. doi: 10.1530/ERC-11-0066. Print 2011 Oct. Review.

35.

Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin.

Berezov A, Cai Z, Freudenberg JA, Zhang H, Cheng X, Thompson T, Murali R, Greene MI, Wang Q.

Oncogene. 2012 Apr 12;31(15):1938-48. doi: 10.1038/onc.2011.377. Epub 2011 Sep 5.

36.

Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.

Zhou H, Zha Z, Liu Y, Zhang H, Zhu J, Hu S, Shen G, Cheng L, Niu L, Greene MI, Teng M, Liu J.

J Biol Chem. 2011 Sep 9;286(36):31676-83. doi: 10.1074/jbc.M111.235184. Epub 2011 Jun 16.

37.

Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent.

Ponde DE, Su Z, Berezov A, Zhang H, Alavi A, Greene MI, Murali R.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2550-3. doi: 10.1016/j.bmcl.2011.02.013. Epub 2011 Feb 15.

38.

Cooperative regulatory events and Foxp3 expression.

Tone M, Greene MI.

Nat Immunol. 2011 Jan;12(1):14-6. doi: 10.1038/ni0111-14. No abstract available.

39.

Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.

Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, GEMO Study Collaborators, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Roozendaal KE; HEBON Study Collaborators, Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, Blank SV, Caldés T, de la Hoya M, Nevanlinna H, Aittomäki K, Lazaro C, Blanco I, Arason A, Johannsson OT, Barkardottir RB, Devilee P, Olopade OI, Neuhausen SL, Wang X, Fredericksen ZS, Peterlongo P, Manoukian S, Barile M, Viel A, Radice P, Phelan CM, Narod S, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN, Toland AE, Montagna M, D'Andrea E, Friedman E, Laitman Y, Borg A, Beattie M, Ramus SJ, Domchek SM, Nathanson KL, Rebbeck T, Spurdle AB, Chen X, Holland H; kConFab, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Overeem Hansen TV, Nielsen FC, Greene MH, Mai PL, Osorio A, Durán M, Andres R, Benítez J, Weitzel JN, Garber J, Hamann U; EMBRACE, Peock S, Cook M, Oliver C, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Walker L, Eason J, Barwell J, Godwin AK, Schmutzler RK, Wappenschmidt B, Engert S, Arnold N, Gadzicki D, Dean M, Gold B, Klein RJ, Couch FJ, Chenevix-Trench G, Easton DF, Daly MJ, Antoniou AC, Altshuler DM, Offit K.

PLoS Genet. 2010 Oct 28;6(10):e1001183. doi: 10.1371/journal.pgen.1001183. Erratum in: PLoS Genet. 2010;6(11). doi: 10.1371/annotation/59ea8540-4e63-4f4a-a79e-f68765fdeac7. Greene, Mark I [corrected to Greene, Mark H]. PLoS Genet. 2010;6(11). doi: 10.1371/annotation/b28cf02d-7196-4a16-8b36-6562a0b84f75. EMBRACE [added].

40.

Regulation of the immune response.

Greene MI, Waldmann H.

Curr Opin Immunol. 2010 Oct;22(5):549-51. doi: 10.1016/j.coi.2010.09.004. Epub 2010 Oct 16. No abstract available.

PMID:
20956073
41.

The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.

Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Wang Q, Greene MI, Hasegawa T, Hirata K, Asaka M, Sato N.

Exp Mol Pathol. 2011 Feb;90(1):55-60. doi: 10.1016/j.yexmp.2010.10.001. Epub 2010 Oct 13.

PMID:
20950610
42.

Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function.

Xiao Y, Li B, Zhou Z, Hancock WW, Zhang H, Greene MI.

Curr Opin Immunol. 2010 Oct;22(5):583-91. doi: 10.1016/j.coi.2010.08.013. Epub 2010 Sep 24. Review.

43.

Targeting erbB receptors.

Cai Z, Zhang H, Liu J, Berezov A, Murali R, Wang Q, Greene MI.

Semin Cell Dev Biol. 2010 Dec;21(9):961-6. doi: 10.1016/j.semcdb.2010.09.005. Epub 2010 Sep 17. Review.

PMID:
20850557
44.

Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Zhang G, Zhang H, Wang Q, Lal P, Carroll AM, de la Llera-Moya M, Xu X, Greene MI.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):732-7. doi: 10.1073/pnas.0911397107. Epub 2009 Dec 18.

45.

Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome.

Ruan Q, Kameswaran V, Tone Y, Li L, Liou HC, Greene MI, Tone M, Chen YH.

Immunity. 2009 Dec 18;31(6):932-40. doi: 10.1016/j.immuni.2009.10.006.

46.

Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism for aneuploidy in cancer.

Liu Q, Hirohashi Y, Du X, Greene MI, Wang Q.

Exp Mol Pathol. 2010 Apr;88(2):225-33. doi: 10.1016/j.yexmp.2009.12.004. Epub 2009 Dec 23.

47.

Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.

Wang L, de Zoeten EF, Greene MI, Hancock WW.

Nat Rev Drug Discov. 2009 Dec;8(12):969-81. doi: 10.1038/nrd3031. Epub 2009 Oct 26. Review.

48.

Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma.

Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriyama K, Nakazawa E, Harada K, Takasu H, Tamura Y, Kamiguchi K, Asanuma H, Tsuruma T, Terui T, Ishitani K, Ohmura T, Wang Q, Greene MI, Hasegawa T, Hirata K, Sato N.

J Immunother. 2009 Jun;32(5):474-85. doi: 10.1097/CJI.0b013e3181a1d109.

PMID:
19609239
49.

Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis.

Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW, Greene MI.

Exp Mol Pathol. 2009 Oct;87(2):99-104. doi: 10.1016/j.yexmp.2009.06.003. Epub 2009 Jul 3.

50.

Structural aspects of the FOXP3 regulatory complex as an immunopharmacological target.

Zhou Z, Song X, Berezov A, Li B, Greene MI.

Int Immunopharmacol. 2009 May;9(5):518-20. doi: 10.1016/j.intimp.2009.01.018. Epub 2009 Jan 29.

PMID:
19539569

Supplemental Content

Loading ...
Support Center